Intelligence Feed event · Equity · 2026-10-07

    Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 Readout

    Question

    Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 Readout

    Direct answer

    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present clinical updates on Licaminlimab at the Eyecelerator showcase at AAO 2026 in Chicago on October 8. Licaminlimab is an investigational topical biologic designed to inhibit TNF alpha signaling in TNFR1-mediated ocular conditions. The company confirmed that the registrational PREDICT-1 clinical study is proceeding according to guidance, with topline data readout scheduled around year-end. Positive registrational efficacy would represent a significant catalyst in the ophthalmic anti-inflammatory pharmaceutical category.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-data-at-aao-2026-ahead-of-predict-1-readout-884bfb

    EQUITY
    Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present clinical updates on Licaminlimab at the Eyecelerator showcase at AAO 2026 in Chicago on October 8. Licaminlimab is an investigational topical biologic designed to inhibit TNF alpha signaling in TNFR1-mediated ocular conditions. The company confirmed that the registrational PREDICT-1 clinical study is proceeding according to guidance, with topline data readout scheduled around year-end. Positive registrational efficacy would represent a significant catalyst in the ophthalmic anti-inflammatory pharmaceutical category.
    OCS
    Impact
    55
    OCT 7
    SIG
    85%
    OCS
    Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 Readout
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present clinical updates on Licaminlimab at the Eyecelerator showcase at AAO 2026 in Chicago on October 8. Licaminlimab is an investigational topical biologic designed to inhibit TNF alpha signaling in TNFR1-mediated ocular conditions. The company confirmed that the registrational PREDICT-1 clinical study is proceeding according to guidance, with topline data readout scheduled around year-end. Positive registrational efficacy would represent a significant catalyst in the ophthalmic anti-inflammatory pharmaceutical category.
    → Clinical trial progression for topical anti-TNF alpha candidate Licaminlimab shifts OCS equity valuation ahead of year-end PREDICT-1 registrational trial readouts.
    Impact
    Biopharmaceutical firm Oculis announced that Chief Executive Officer Riad Sherif will present clinical updates on Licaminlimab at the Eyecelerator showcase at AAO 2026 in Chicago on October 8. Licaminlimab is an investigational topical biologic designed to inhibit TNF alpha signaling in TNFR1-mediated ocular conditions. The company confirmed that the registrational PREDICT-1 clinical study is proceeding according to guidance, with topline data readout scheduled around year-end. Positive registrational efficacy would represent a significant catalyst in the ophthalmic anti-inflammatory pharmaceutical category.
    Affected
    OCS
    Transmission
    Clinical trial progression for topical anti-TNF alpha candidate Licaminlimab shifts OCS equity valuation ahead of year-end PREDICT-1 registrational trial readouts.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiotech registrational clinical trial readout milestonesUp1-3mOculis announced AAO presentation and affirmed year-end PREDICT-1 trial readout.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month